Your browser doesn't support javascript.
loading
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda.
Namara-Lugolobi, Emily; Namukwaya, Zikulah; Owor, Maxensia; Ouma, Joseph; Namale-Matovu, Joyce; Nakabiito, Clemensia; Ndugwa, Christopher; Fowler, Mary Glenn; Musoke, Phillipa.
Afiliação
  • Namara-Lugolobi E; Makerere University-Johns Hopkins University Research Collaboration.
  • Namukwaya Z; Makerere University Infectious Diseases Institute, Makerere College of Health Sciences.
  • Owor M; Makerere University-Johns Hopkins University Research Collaboration.
  • Ouma J; Makerere University-Johns Hopkins University Research Collaboration.
  • Namale-Matovu J; Makerere University-Johns Hopkins University Research Collaboration.
  • Nakabiito C; Makerere University-Johns Hopkins University Research Collaboration.
  • Ndugwa C; Makerere University-Johns Hopkins University Research Collaboration.
  • Fowler MG; Makerere University-Johns Hopkins University Research Collaboration.
  • Musoke P; Makerere University-Johns Hopkins University Research Collaboration.
Afr Health Sci ; 22(Spec Issue): 22-33, 2022 Aug.
Article em En | MEDLINE | ID: mdl-36321115
Background: Over 90% of new paediatric HIV infections are acquired through mother to child transmission. Prevention of mother to child HIV transmission (PMTCT) research in sub-Saharan Africa informed WHO guidelines which enabled implementation of PMTCT programs globally. Objectives: To describe Makerere University-Johns Hopkins University (MU-JHU) perinatal HIV prevention research and implementation of the Mulago National Referral Hospital (MNRH) PMTCT program. Methods: Perinatal HIV prevention studies conducted at MU-JHU between 1997-2016 were summarized. Program aggregated data was extracted and analyzed using STATA 15. Results: In 1999, the HIVNET 012 study demonstrated that single-dose nevirapine (sdNVP) to the mother at onset of labor and to her newborn, reduced MTCT by nearly 50%. In 2016, the PROMISE study documented the safety and efficacy of ART during pregnancy and breastfeeding period. Program implementation at MNRH started in 2000. Uptake of HIV testing increased from 70% to 99% from 2006 onwards. sd NVP was the initial ARV regimen but by 2012, MOH recommended Option B+(triple therapy). MTCT rates reduced from 16.9% in 2001 to 2.3% in 2020. Conclusion: Perinatal HIV prevention clinical trials conducted at MU-JHU provided evidence to inform WHO PMTCT guidelines. MNRH program evaluation demonstrated the significant decline in MTCT rates over the last two decades.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complicações Infecciosas na Gravidez / Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Guideline Limite: Child / Female / Humans / Newborn / Pregnancy País/Região como assunto: Africa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complicações Infecciosas na Gravidez / Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Guideline Limite: Child / Female / Humans / Newborn / Pregnancy País/Região como assunto: Africa Idioma: En Ano de publicação: 2022 Tipo de documento: Article